IL215660A0 - 5-ht4 receptor agonist compounds for treatment of cognitive disorders - Google Patents
5-ht4 receptor agonist compounds for treatment of cognitive disordersInfo
- Publication number
- IL215660A0 IL215660A0 IL215660A IL21566011A IL215660A0 IL 215660 A0 IL215660 A0 IL 215660A0 IL 215660 A IL215660 A IL 215660A IL 21566011 A IL21566011 A IL 21566011A IL 215660 A0 IL215660 A0 IL 215660A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- receptor agonist
- cognitive disorders
- agonist compounds
- compounds
- Prior art date
Links
- 108091005482 5-HT4 receptors Proteins 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16874109P | 2009-04-13 | 2009-04-13 | |
| US29255910P | 2010-01-06 | 2010-01-06 | |
| PCT/US2010/030760 WO2010120695A2 (en) | 2009-04-13 | 2010-04-12 | 5-ht4 receptor agonist compounds for treatment of cognitive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL215660A0 true IL215660A0 (en) | 2012-01-31 |
Family
ID=42237213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL215660A IL215660A0 (en) | 2009-04-13 | 2011-10-10 | 5-ht4 receptor agonist compounds for treatment of cognitive disorders |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8404711B2 (enExample) |
| EP (1) | EP2419104B1 (enExample) |
| JP (1) | JP2012523437A (enExample) |
| KR (1) | KR20120017421A (enExample) |
| CN (2) | CN105832735A (enExample) |
| AU (1) | AU2010236734B2 (enExample) |
| BR (1) | BRPI1013777A8 (enExample) |
| CA (1) | CA2758321A1 (enExample) |
| CY (1) | CY1119800T1 (enExample) |
| DK (1) | DK2419104T3 (enExample) |
| ES (1) | ES2654930T3 (enExample) |
| HR (1) | HRP20180018T1 (enExample) |
| HU (1) | HUE038141T2 (enExample) |
| IL (1) | IL215660A0 (enExample) |
| LT (1) | LT2419104T (enExample) |
| MX (1) | MX2011010782A (enExample) |
| NO (1) | NO2419104T3 (enExample) |
| PL (1) | PL2419104T3 (enExample) |
| PT (1) | PT2419104T (enExample) |
| RU (1) | RU2569056C2 (enExample) |
| SI (1) | SI2419104T1 (enExample) |
| SM (1) | SMT201800036T1 (enExample) |
| WO (1) | WO2010120695A2 (enExample) |
| ZA (1) | ZA201107490B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| HUE037938T2 (hu) | 2008-11-19 | 2018-09-28 | Forum Pharmaceuticals Inc | Skizofrénia negatív tüneteinek kezelése (R)-7-klór-N-(kinuklidin-3-il)benzo[b]tiofén-2-karboxamiddal és ennek gyógyszerészetileg elfogadható sójával |
| JP5808319B2 (ja) * | 2009-05-11 | 2015-11-10 | フォルム ファーマシューティカルズ、インコーポレイテッド | アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療 |
| ES2570657T3 (es) | 2010-05-17 | 2016-05-19 | Forum Pharmaceuticals Inc | Una forma cristalina de hidrocloruro de (R)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidrato |
| WO2013169646A1 (en) | 2012-05-08 | 2013-11-14 | Envivo Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| CN104781390B (zh) | 2012-08-16 | 2017-07-28 | 庆熙大学校产学协力团 | 具有对衰老及痴呆的预防和/或治疗活性的乳酸菌 |
| US10874701B2 (en) | 2012-08-16 | 2020-12-29 | University-Industry Cooperation Group Of Kyung Hee University | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
| JP7167065B2 (ja) | 2017-05-24 | 2022-11-08 | ハー・ルンドベック・アクチエゼルスカベット | Ａｐｏｅ４アレルを有する患者亜集団におけるアルツハイマー病の治療での使用のための５－ｈｔ６受容体アンタゴニストとアセチルコリンエステラーゼ阻害剤の組み合わせ |
| SG11201909359YA (en) | 2017-06-01 | 2019-11-28 | Eisai R&D Man Co Ltd | Pharmaceutical composition comprising pde9 inhibitor |
| RU2759727C2 (ru) | 2017-06-02 | 2021-11-17 | ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. | Средство для профилактики или лечения атрофии головного мозга |
| SG11201912266QA (en) * | 2017-07-31 | 2020-01-30 | Theravance Biopharma R&D Ip Llc | Methods of treating symptoms of gastroparesis using velusetrag |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001249091A1 (en) * | 2000-03-03 | 2001-09-17 | Eisai Co. Ltd. | Novel methods using cholinesterase inhibitors |
| TWI351282B (en) * | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US7598265B2 (en) * | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| TWI377206B (en) * | 2005-04-06 | 2012-11-21 | Theravance Inc | Crystalline form of a quinolinone-carboxamide compound |
| MY147756A (en) * | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
-
2010
- 2010-04-12 LT LTEP10713790.3T patent/LT2419104T/lt unknown
- 2010-04-12 PL PL10713790T patent/PL2419104T3/pl unknown
- 2010-04-12 WO PCT/US2010/030760 patent/WO2010120695A2/en not_active Ceased
- 2010-04-12 BR BRPI1013777A patent/BRPI1013777A8/pt not_active IP Right Cessation
- 2010-04-12 PT PT107137903T patent/PT2419104T/pt unknown
- 2010-04-12 HU HUE10713790A patent/HUE038141T2/hu unknown
- 2010-04-12 SM SM20180036T patent/SMT201800036T1/it unknown
- 2010-04-12 KR KR1020117026729A patent/KR20120017421A/ko not_active Ceased
- 2010-04-12 CN CN201610257689.5A patent/CN105832735A/zh active Pending
- 2010-04-12 ES ES10713790.3T patent/ES2654930T3/es active Active
- 2010-04-12 AU AU2010236734A patent/AU2010236734B2/en not_active Ceased
- 2010-04-12 DK DK10713790.3T patent/DK2419104T3/en active
- 2010-04-12 EP EP10713790.3A patent/EP2419104B1/en active Active
- 2010-04-12 RU RU2011146032/15A patent/RU2569056C2/ru not_active IP Right Cessation
- 2010-04-12 HR HRP20180018TT patent/HRP20180018T1/hr unknown
- 2010-04-12 MX MX2011010782A patent/MX2011010782A/es active IP Right Grant
- 2010-04-12 NO NO10713790A patent/NO2419104T3/no unknown
- 2010-04-12 SI SI201031632T patent/SI2419104T1/en unknown
- 2010-04-12 CA CA2758321A patent/CA2758321A1/en not_active Abandoned
- 2010-04-12 US US12/758,631 patent/US8404711B2/en not_active Expired - Fee Related
- 2010-04-12 CN CN2010800164976A patent/CN102395371A/zh active Pending
- 2010-04-12 JP JP2012504924A patent/JP2012523437A/ja active Pending
-
2011
- 2011-10-10 IL IL215660A patent/IL215660A0/en unknown
- 2011-10-12 ZA ZA2011/07490A patent/ZA201107490B/en unknown
-
2013
- 2013-02-20 US US13/771,685 patent/US20140057939A1/en not_active Abandoned
-
2018
- 2018-01-19 CY CY20181100069T patent/CY1119800T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010236734A1 (en) | 2011-11-03 |
| BRPI1013777A2 (pt) | 2016-04-05 |
| ZA201107490B (en) | 2012-06-27 |
| PT2419104T (pt) | 2018-01-31 |
| WO2010120695A2 (en) | 2010-10-21 |
| CN105832735A (zh) | 2016-08-10 |
| AU2010236734B2 (en) | 2015-06-11 |
| MX2011010782A (es) | 2012-01-20 |
| HRP20180018T1 (hr) | 2018-02-09 |
| RU2011146032A (ru) | 2013-05-20 |
| CY1119800T1 (el) | 2018-06-27 |
| EP2419104A2 (en) | 2012-02-22 |
| RU2569056C2 (ru) | 2015-11-20 |
| BRPI1013777A8 (pt) | 2017-09-19 |
| WO2010120695A3 (en) | 2010-12-02 |
| US8404711B2 (en) | 2013-03-26 |
| CA2758321A1 (en) | 2010-10-21 |
| SI2419104T1 (en) | 2018-03-30 |
| DK2419104T3 (en) | 2018-02-05 |
| AU2010236734A8 (en) | 2012-02-16 |
| US20100261752A1 (en) | 2010-10-14 |
| KR20120017421A (ko) | 2012-02-28 |
| NO2419104T3 (enExample) | 2018-04-07 |
| JP2012523437A (ja) | 2012-10-04 |
| SMT201800036T1 (it) | 2018-03-08 |
| ES2654930T3 (es) | 2018-02-15 |
| CN102395371A (zh) | 2012-03-28 |
| HUE038141T2 (hu) | 2018-10-29 |
| US20140057939A1 (en) | 2014-02-27 |
| EP2419104B1 (en) | 2017-11-08 |
| PL2419104T3 (pl) | 2018-04-30 |
| LT2419104T (lt) | 2018-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL215660A0 (en) | 5-ht4 receptor agonist compounds for treatment of cognitive disorders | |
| EP2467372A4 (en) | TREATMENT OF BDNF ASSOCIATED DISEASES WITH LAQUINIMOD | |
| HUE044653T2 (hu) | Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk | |
| IL215131A (en) | A mixture of compounds for use in therapy | |
| IL225758A0 (en) | Preparations containing combinations of serotonin agonists and their uses | |
| EP2414824A4 (en) | BIOMARKERS FOR MONITORING THE TREATMENT OF NEUROPSYCHIATRIC ILLNESSES | |
| ZA201107449B (en) | Compounds for the treatment of metabolic disorders | |
| ZA201107446B (en) | Compounds for the treatment of metabolic disorders | |
| GB0904284D0 (en) | Compounds for the treatment of metabolic disorders | |
| ZA201106076B (en) | Treatment of insulin-resistant disorders | |
| ZA201204391B (en) | Compounds for the treatment of neurologic disorders | |
| ZA200908724B (en) | Spiro compounds for treatment of inflammatory disorders | |
| ZA201107708B (en) | Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain | |
| GB201012926D0 (en) | Compounds for treatment of inflammation | |
| ZA201202379B (en) | Antagonists of dsgs2 for treatment of cancer | |
| HK1188927A (en) | Combinations of serotonin receptor agonists for treatment of movement disorders | |
| GB0906222D0 (en) | Methods for screening of therapeutic agents | |
| GB0913427D0 (en) | Compounds for treatment of imflammation | |
| HU0900722D0 (en) | Compounds for the treatment of neurological disorders | |
| HK1177888A (en) | 5-ht4 receptor agonists for the treatment of dementia | |
| GB0904286D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB0904290D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB0904289D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB0904288D0 (en) | Compounds for the treatment of metabolic disorders |